The skeleton is an efficient 'servo' (feedback-controlled/steady-state) system that continuously integrates signals and responses which sustain its functions of delivering calcium while maintaining strength. In many individuals, bone mass homeostasis starts failing in midlife, leading to bone loss, osteoporosis and debilitating fractures. Recent advances, spearheaded by genetic information, offer the opportunity to stop or reverse this downhill course.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Circulating Extracellular Vesicles Express Receptor Activator of Nuclear Factor κB Ligand and Other Molecules Informative of the Bone Metabolic Status of Mouse Models of Experimentally Induced Osteoporosis
Calcified Tissue International Open Access 25 October 2022
Ano5 modulates calcium signaling during bone homeostasis in gnathodiaphyseal dysplasia
npj Genomic Medicine Open Access 18 August 2022
Low-dose IL-34 has no effect on osteoclastogenesis but promotes osteogenesis of hBMSCs partly via activation of the PI3K/AKT and ERK signaling pathways
Stem Cell Research & Therapy Open Access 04 May 2021
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
Rodan, G. A. Bone mass homeostasis and bisphosphonate action. Bone 20, 1–4 (1997).
Ehrlich, P. J. & Lanyon, L. E. Mechanical strain and bone cell function: a review. Osteoporosis Int. 13, 688–700 (2002).
Pavalko, F. M. et al. A Model for mechanotransduction in bone cells: The load-bearing mechanosomes. J. Cell. Biochem. 88, 104–112 (2003).
Riggs, B. L., Khosla, S. & Melton, L. J. III Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279–302 (2002).
Schmidt, A., Harada, S. & Rodan, G. A. in Principles of Bone Biology (eds Bilezikian, J. P., Raisz, L. G. & Rodan, G. A.) 1455–1466 (Academic, San Diego, 2002).
Frost, H. M. Cybernetic aspects of bone modeling and remodeling with special reference to osteoporosis and whole-bone strength. Am. J. Hum. Biol. 13, 235–248 (2001).
Martin, T. J. & Rodan, G. A. in Osteoporosis (eds Marcus, R., Feldman, D. & Kelsey, J.) 361–371 (Academic, San Diego, 2002).
Pocock, N. A. et al. Genetic determinants of bone mass in adults. A twin study. J. Clin. Invest. 80, 706–710 (1987).
Seeman, E. et al. Reduced bone mass in daughters of women with osteoporosis. N. Engl. J. Med. 320, 554–558 (1989).
Ralston, S. H. Genetic control of susceptibility to osteoporosis. J. Clin. Endocrinol. Metab. 87, 2460–2466 (2002).
Mosekilde, L. Consequences of the remodelling process for vertebral trabecular bone structure: a scanning electron microscopy study (uncoupling of unloaded structures). Bone Miner. 10, 13–35 (1990).
Wallace, B. A. & Cumming, R. G. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif. Tissue Int. 67, 10–18 (2000).
Kontulainen, S. et al. Good maintenance of exercise-induced bone gain with decreased training of female tennis and squash players: a prospective 5-year follow-up study of young and old starters and controls. J. Bone Miner. Res. 16, 195–201 (2001).
Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197–207 (2000).
Corral, D. A. et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl Acad. Sci. USA 95, 13835–13840 (1998).
Takeda, S. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111, 305–317 (2002).
Thomas, T. et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140, 1630–1638 (1999).
Burguera, B. et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142, 3546–3553 (2001).
Khosla, S. Leptin-central or peripheral to the regulation of bone metabolism? Endocrinology 143, 4161–4164 (2002).
Bliziotes, M. et al. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 26, 15–19 (2000).
Baldock, P. A. et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109, 915–921 (2002).
Thorsell, A. & Heilig, M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides 36, 182–193 (2002).
Mahns, D. A., Lacroix, J. S. & Potter, E. K. Inhibition of vagal vasodilatation by a selective neuropeptide Y Y2 receptor agonist in the bronchial circulation of anaesthetised dogs. J. Auton. Nerv. Syst. 73, 80–85 (1998).
Smith-White, M. A., Herzog, H. & Potter, E. K. Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul. Pept. 103, 105–111 (2002).
Flier, J. S. Physiology: is brain sympathetic to bone? Nature 420, 619–622 (2002).
Minkowitz, B., Boskey, A. L., Lane, J. M., Pearlman, H. S. & Vigorita, V. J. Effects of propranolol on bone metabolism in the rat. J. Orthop. Res. 9, 869–875 (1991).
Schwartzman, R. J. New treatments for reflex sympathetic dystrophy. N. Engl. J. Med. 343, 654–656 (2000).
Ducy, P., Schinke, T. & Karsenty, G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 289, 1501–1504 (2000).
Rosen, E. D. & Spiegelman, B. M. Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 16, 145–171 (2000).
Arnold, H. H. & Winter, B. Muscle differentiation: more complexity to the network of myogenic regulators. Curr. Opin. Genet. Dev. 8, 539–544 (1998).
Karsenty, G. & Wagner, E. F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2, 389–406 (2002).
Akiyama, H., Chaboissier, M. C., Martin, J. F., Schedl, A. & de Crombrugghe, B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 16, 2813–2828 (2002).
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L. & Karsenty, G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747–754 (1997).
Komori, T. et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755–764 (1997).
Otto, F. et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765–771 (1997).
Inada, M. et al. Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev. Dyn. 214, 279–290 (1999).
Ueta, C. et al. Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. J. Cell Biol. 153, 87–100 (2001).
Takeda, S., Bonnamy, J. P., Owen, M. J., Ducy, P. & Karsenty, G. Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. Genes Dev. 15, 467–481 (2001).
Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002).
Jheon, A. H., Ganss, B., Cheifetz, S. & Sodek, J. Characterization of a novel KRAB/C2H2 zinc finger transcription factor involved in bone development. J. Biol. Chem. 276, 18282–18289 (2001).
Kundu, M. et al. Cbfβ interacts with Runx2 and has a critical role in bone development. Nature Genet. 32, 639–644 (2002).
Yoshida, C. A. et al. Core-binding factor β interacts with Runx2 and is required for skeletal development. Nature Genet. 32, 633–638 (2002).
Bendall, A. J. & Abate-Shen, C. Roles for Msx and Dlx homeoproteins in vertebrate development. Gene 247, 17–31 (2000).
Robledo, R. F., Rajan, L., Li, X. & Lufkin, T. The Dlx5 and Dlx6 homeobox genes are essential for craniofacial, axial, and appendicular skeletal development. Genes Dev. 16, 1089–1101 (2002).
Grigoriadis, A. E., Wang, Z. Q. & Wagner, E. F. Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet. 11, 436–441 (1995).
Jochum, W. et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nature Med. 6, 980–984 (2000).
Sabatakos, G. et al. Overexpression of ΔFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nature Med. 6, 985–990 (2000).
Ducy, P. et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13, 1025–1036 (1999).
Geoffroy, V., Kneissel, M., Fournier, B., Boyde, A. & Matthias, P. High bone resorption in adult aging transgenic mice overexpressing Cbfa1/Runx2 in cells of the osteoblastic lineage. Mol. Cell. Biol. 22, 6222–6233 (2002).
Liu, W. et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155, 157–166 (2001).
Little, R. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11–19 (2002).
Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513–1521 (2002).
Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–523 (2001).
Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157, 303–314 (2002).
Hey, P. J. et al. Cloning of a novel member of the low-density lipoprotein receptor family. Gene 216, 103–111 (1998).
Pinson, K. I., Brennan, J., Monkley, S., Avery, B. J. & Skarnes, W. C. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407, 535–538 (2000).
Mao, J. et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7, 801–809 (2001).
Bain, G., Muller, T., Wang, X. & Papkoff, J. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem. Biophys. Res. Commun. 301, 84–91 (2003).
Zorn, A. M. Wnt signalling: antagonistic Dickkopfs. Curr. Biol. 11, R592–R595 (2001).
Hadjiargyrou, M. et al. Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J. Biol. Chem. 277, 30177–30182 (2002).
Van Wesenbeeck, L. et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72, 763–771 (2003).
Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543 (2001).
Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577–589 (2001).
Balemans, W. & Van Hul, W. Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev. Biol. 250, 231–250 (2002).
Rodan, G. A. & Martin, T. J. Therapeutic approaches to bone diseases. Science 289, 1508–1514 (2000).
Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 417, 664–667 (2002).
We thank C. Hauer and J. Campbell for their assistance with artwork.
Rights and permissions
About this article
Cite this article
Harada, Si., Rodan, G. Control of osteoblast function and regulation of bone mass. Nature 423, 349–355 (2003). https://doi.org/10.1038/nature01660
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.